
W. Kimryn (Kim) Rathmell, M.D., Ph.D.
- Hugh Jackson Morgan Chair in Medicine
- Chair, Department of Medicine
- Physician-in-Chief, Vanderbilt University Medical Center
- Professor of Biochemistry
- Professor of Biochemistry
W. Kimryn (Kim) Rathmell, M.D., Ph.D.
- Hugh Jackson Morgan Chair in Medicine
- Chair, Department of Medicine
- Physician-in-Chief, Vanderbilt University Medical Center
- Professor of Biochemistry
- Professor of Biochemistry
kimryn.rathmell@vumc.org
2220 Pierce Ave
Nashville, TN 37232-6307
Research Program
Departments/Affiliations
Provider Information
Profile
Education
- M.D., Stanford University, Stanford, California (1998)
- Ph.D., Stanford University, Stanford, California (1996)
- B.A., University of Northern Iowa, Cedar Falls, Iowa (1991)
- B.S., University of Northern Iowa, Cedar Falls, Iowa (1991)
Research Emphasis
Renal cell carcinoma
Research Description
As the Chair of the Department of Medicine, I am invested in creating a basic, translational, and clinical program that supports each of our cancer programs.
As a genitourinary oncologist, I focus on renal cell carcinoma. This cancer affects over 70,000 new patients annually in the US. We are interested in understanding all factors intrinsic and extrinsic to the cancer cell that influence tumor growth. Therefore, our research takes a broad approach using genetic, molecular, and cell biology techniques to study tumor-initiating events and events that promote the development of invasive or metastatic features using in vitro, animal, and human systems. This translational research, all geared toward enhancing our understanding of the genetics and molecular biology of hypoxia-driven cancers, is folded into a clinical research program focused on hereditary kidney cancer syndromes at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center.
Publications
- Rathmell JC, Rathmell WK. Pushing the boundaries with collision collaboration: the marriage of ideas. J Clin Invest. 2021 Jan 1/19/2021; 131(2): PMID: 33463534, PMCID: PMC7810468, PII: 145964, DOI: 10.1172/JCI145964, ISSN: 1558-8238.
- Wood CG, Ferguson JE, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, Rathmell WK. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight. 2020 Nov 11/19/2020; 5(22): PMID: 33208553, PMCID: PMC7710285, PII: 132852, DOI: 10.1172/jci.insight.132852, ISSN: 2379-3708.
- Rini B, Abel EJ, Albiges L, Bex A, Brugarolas J, Bukowski RM, Coleman JA, Drake CG, Figlin RA, Futreal A, Hammers H, Powles T, Rathmell WK, Ricketts CJ, Turajlic S, Wood CG, Leibovich BC. Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. Clin Genitourin Cancer [print-electronic]. 2020 Nov 11/14/2020; PMID: 33358149, PII: S1558-7673(20)30234-2, DOI: 10.1016/j.clgc.2020.10.005, ISSN: 1938-0682.
- Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol [print-electronic]. 2020 Nov 11/3/2020; PMID: 33144689, PII: 10.1038/s41581-020-00359-2, DOI: 10.1038/s41581-020-00359-2, ISSN: 1759-507X.
- Seervai RNH, Jangid RK, Karki M, Tripathi DN, Jung SY, Kearns SE, Verhey KJ, Cianfrocco MA, Millis BA, Tyska MJ, Mason FM, Rathmell WK, Park IY, Dere R, Walker CL. The Huntingtin-interacting protein SETD2/HYPB is an actin lysine methyltransferase. Sci Adv [electronic-print]. 2020 Oct; 6(40): PMID: 33008892, PMCID: PMC7852384, PII: 6/40/eabb7854, DOI: 10.1126/sciadv.abb7854, ISSN: 2375-2548.
- Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE, . Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol [print-electronic]. 2020 Sep 9/16/2020; PMID: 32936333, PII: 10.1007/s00345-020-03441-3, DOI: 10.1007/s00345-020-03441-3, ISSN: 1433-8726.
- Vilgelm AE, Bergdorf K, Wolf M, Bharti V, Shattuck-Brandt R, Blevins A, Jones C, Phifer C, Lee M, Lowe C, Hongo R, Boyd K, Netterville J, Rohde S, Idrees K, Bauer JA, Westover D, Reinfeld B, Baregamian N, Richmond A, Rathmell WK, Lee E, McDonald OG, Weiss VL. Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids. IScience [print-electronic]. 2020 Aug 8/21/2020; 23(8): 101408. PMID: 32771978, PMCID: PMC7415927, PII: S2589-0042(20)30598-8, DOI: 10.1016/j.isci.2020.101408, ISSN: 2589-0042.
- Beckermann KE, Hongo R, Ye X, Young K, Carbonell K, Healey DCC, Siska PJ, Barone S, Roe CE, Smith CC, Vincent BG, Mason FM, Irish JM, Rathmell WK, Rathmell JC. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. JCI Insight. 2020 Aug 8/20/2020; 5(16): PMID: 32814710, PMCID: PMC7455120, PII: 138729, DOI: 10.1172/jci.insight.138729, ISSN: 2379-3708.
- Bacigalupa ZA, Rathmell WK. Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma. Cancer Lett [print-electronic]. 2020 Jun 6/5/2020; PMID: 32512023, PII: S0304-3835(20)30296-2, DOI: 10.1016/j.canlet.2020.05.034, ISSN: 1872-7980.
- Levine RL, Rathmell WK. COVID-19 impact on early career investigators: a call for action. Nat. Rev. Cancer [print-electronic]. 2020 Jun 6/5/2020; PMID: 32503987, PMCID: PMC7273376, PII: 10.1038/s41568-020-0279-5, DOI: 10.1038/s41568-020-0279-5, ISSN: 1474-1768.